Colorectal Cancer | Specialty

Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy

September 18th 2019

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Dr. Manji on Treatment for NTRK Fusion+ CRC

September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

Key Takeaway 8: MSI-High Status and HER2 Amplification

September 16th 2019

Key Takeaway 7: Role of Immunotherapy in MSI-High MCRC

September 16th 2019

Key Takeaway 6: I/O: Combination vs Monotherapy

September 16th 2019

Key Takeaway 5: Dosing of Multiple Kinase Inhibitors

September 16th 2019

Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment

September 16th 2019

Key Takeaway 3: Determining Tumor Mutational Status

September 16th 2019

Key Takeaway 2: Frontline Neoadjuvant Chemotherapy

September 16th 2019

Key Takeaway 1: Adjuvant Therapy Optimal Duration

September 16th 2019

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Dr. Fakih on Future Directions in CRC

September 6th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).

Shorter Adjuvant Oxaliplatin-Based Therapy Less Effective in High-Risk Stage II CRC

September 6th 2019

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.

Dr. Manji on Treatment for Right-Sided Tumors in CRC

September 4th 2019

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

Dr. Lenz on the Safety Profile in CheckMate-142 Trial in CRC

August 28th 2019

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC

August 23rd 2019

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer

August 21st 2019

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

Dr. Lee on Data Regarding HIPEC in mCRC

August 20th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

ctDNA Testing Now Valuable Tool in CRC, Next Steps Underway

August 20th 2019

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

Dr. Manji on Treatment for BRAF-Mutant CRC

August 16th 2019

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.